FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2008
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

KUCHERLAPATI RAJU S 		2. Issuer Name and Ticker or Trading Symbol

MILLENNIUM PHARMACEUTICALS INC [ MLNM ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

77 LOUIS PASTEUR AVENUE, SUITE 250 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/14/2008
(Street)

BOSTON, MA 02115
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy)   $19.76   5/14/2008     D        2667      (1) 5/1/2012   Common Stock   2667   $0   0   D    
Stock option (right to buy)   $15.09   5/14/2008     D        2667      (1) 6/1/2012   Common Stock   2667   $0   0   D    
Stock option (right to buy)   $11.00   5/14/2008     D        2666      (1) 7/1/2012   Common Stock   2666   $0   0   D    
Stock option (right to buy)   $11.61   5/14/2008     D        5167      (1) 5/1/2013   Common Stock   5167   $0   0   D    
Stock option (right to buy)   $15.55   5/14/2008     D        5167      (1) 6/1/2013   Common Stock   5167   $0   0   D    
Stock option (right to buy)   $14.00   5/14/2008     D        5166      (1) 7/1/2013   Common Stock   5166   $0   0   D    
Stock option (right to buy)   $15.02   5/14/2008     D        5000      (1) 5/1/2014   Common Stock   5000   $0   0   D    
Stock option (right to buy)   $15.20   5/14/2008     D        5000      (1) 6/1/2014   Common Stock   5000   $0   0   D    
Stock option (right to buy)   $13.28   5/14/2008     D        5000      (1) 7/1/2014   Common Stock   5000   $0   0   D    
Stock option (right to buy)   $8.70   5/14/2008     D        5167      (1) 5/1/2015   Common Stock   5167   $0   0   D    
Stock option (right to buy)   $8.33   5/14/2008     D        6167      (1) 6/1/2015   Common Stock   6167   $0   0   D    
Stock option (right to buy)   $9.17   5/14/2008     D        6166      (1) 7/1/2015   Common Stock   6166   $0   0   D    
Stock option (right to buy)   $8.99   5/14/2008     D        5834      (1) 5/1/2016   Common Stock   5834   $0   0   D    
Stock option (right to buy)   $8.36   5/14/2008     D        5833      (1) 6/1/2016   Common Stock   5833   $0   0   D    
Stock option (right to buy)   $9.97   5/14/2008     D        5833      (1) 7/1/2016   Common Stock   5833   $0   0   D    
Stock option (right to buy)   $10.99   5/14/2008     D        5834      (1) 5/1/2017   Common Stock   5834   $0   0   D    
Stock option (right to buy)   $10.87   5/14/2008     D        16666      (1) 5/31/2017   Common Stock   16666   $0   0   D    
Restricted stock units     (2) 5/14/2008     D        5000      (3)   (3) Common Stock   5000   $0   0   D    

Explanation of Responses:
( 1)  This option was cancelled in the merger (the "Merger") of Mahogany Acquisition Corp. with and into Millennium Pharmaceuticals, Inc. ("Millennium") in exchange for a cash payment per underlying share equal to the difference between the exercise price and $25.00.
( 2)  Each restricted stock unit represents a contingent right to receive one share of Millennium common stock.
( 3)  Each restricted stock unit award was cancelled in the Merger in exchange for $25.00 per share of Millennium common stock underlying the restricted stock unit award.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
KUCHERLAPATI RAJU S
77 LOUIS PASTEUR AVENUE
SUITE 250
BOSTON, MA 02115 		X



Signatures
Joel S. Goldberg, Attorney-In-Fact 5/15/2008
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Millennium Pharmaceuticals (MM) (NASDAQ:MLNM)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Millennium Pharmaceuticals (MM) Charts.
Millennium Pharmaceuticals (MM) (NASDAQ:MLNM)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Millennium Pharmaceuticals (MM) Charts.